Kanisa Pharmaceuticals Frequently Asked Questions (FAQ)
Where is Kanisa Pharmaceuticals's headquarters?
Kanisa Pharmaceuticals's headquarters is located at 12264 El Camino Real, San Diego.
What is Kanisa Pharmaceuticals's latest funding round?
Kanisa Pharmaceuticals's latest funding round is Series A.
How much did Kanisa Pharmaceuticals raise?
Kanisa Pharmaceuticals raised a total of $25M.
Who are the investors of Kanisa Pharmaceuticals?
Investors of Kanisa Pharmaceuticals include New Enterprise Associates, InterWest Partners, Lilly Ventures, Montreux Equity Partners, Windamere Venture Partners and 3 more.
Who are Kanisa Pharmaceuticals's competitors?
Competitors of Kanisa Pharmaceuticals include Zogenix, Constellation Pharmaceuticals, Neos Therapeutics, OcuNexus Therapeutics, Aquinox Pharmaceuticals and 7 more.
Compare Kanisa Pharmaceuticals to Competitors
VGXI is a Contract Development and Manufacturing Organization (CDMO) specializing in the production of DNA plasmids for various applications including human clinical trials, virus production, and pre-clinical research. The company offers services such as cGMP compliant manufacturing of injectable-grade plasmid DNA, as well as high purity plasmid preparations for pre-clinical stages. VGXI's patented AIRMIX lysis technology facilitates the creation of high purity, highly concentrated plasmid formulations. It is based in Spring, Texas.
Adastra Pharmaceuticals is a clinical-stage biopharmaceutical company with a primary focus on oncology. The company is dedicated to developing innovative treatments for aggressive forms of cancer. Its primary customer base is within the healthcare industry, specifically those dealing with oncology. Adastra Pharmaceuticals was formerly known as Tragara Pharmaceuticals. It was founded in 2005 and is based in Princeton, New Jersey.
Anexon, Inc., a pharmaceutical company, develops therapeutics for cardiovascular diseases. The company is based in Cambridge, Massachusetts.
CoImmune is a company that focuses on the development and manufacture of cell-based therapeutics, operating within the healthcare and biotechnology sectors. The company's main offerings include treatments for unmet medical needs such as cancer, autoimmune, and inflammatory diseases. It was founded in 1997 and is based in Durham, North Carolina. CoImmune operates as a subsidiary of Genexine and SCM Lifescience.
Aderis Pharmaceuticals, formerly Discovery Therapeutics, develops and commercializes small molecule, receptor-specific therapeutics for the treatment of central nervous system, cardiovascular and renal diseases.
Zinc Therapeutics Canada Inc is focusing on development of new zinc-containing therapeutic compounds for heart, stroke and other disorders.